Freeline’s Rare Disease Gene Therapies Get €72M Series C Boost
The UK gene therapy biotech Freeline Therapeutics is to receive an investment worth €72M (£61.1M)…
The UK gene therapy biotech Freeline Therapeutics is to receive an investment worth €72M (£61.1M)…
A gene therapy developed by the Dutch biotech uniQure increased the activity of a blood…
uniQure has raised a substantial public offering on the NASDAQ. The funding could help the Dutch…
Rare diseases affect fewer than 1 in 2,000 people in Europe and less than 200,000…
Experts say hemophilia treatment is at a 'precipice of a therapeutic revolution.' From antibodies to…
We love hearing from our readers, and we listen to what they like! Here are…
UniQure has published clinical data revealing that its gene therapy for hemophilia B is effective…
Now that we've got the bad news out of the way, we're here to spread…
Over 10,000 human diseases are caused by exactly one faulty gene. Gene therapy promises to fix…
Update (2/11/2017): uniQure has closed its public offering raising over $91m (€78M) on the Nasdaq, taking advantage…
uniQure is getting ready to start a Phase III clinical trial in 2018 with a…
Bicycle Therapeutics has partnered with Bioverativ to develop a new class of drugs for patients…